Tarsus Pharmaceuticals Inc (TARS NASDAQ) stock market data APIs
$40.7878
-0.67(-1.6%)
as of July 3, 2025
Try our APIs with
free plan!
Tarsus Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Prev. Close
40.7878
Open
40.1187
High
41.6603
Low
39.6928
52 wk Range
20.0818-57.28
Market Cap
1 699 M
Shares Outstanding
42 014 K
Revenue
234 M
EPS
-0.64
Beta
0.836
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tarsus Pharmaceuticals Inc data using free add-ons & libraries
Get Tarsus Pharmaceuticals Inc Fundamental Data
Tarsus Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 234 M
- EBITDA: -107 750 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.63
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tarsus Pharmaceuticals Inc News
New
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wi...
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcomin...
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) has been beaten down lately with too much selling pressure. While the stock has lost 15.6% over the past four weeks, there is light at the end of the tunnel as it i...
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
